Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients.
Mult Scler Relat Disord
; 82: 105412, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38198989
ABSTRACT
BACKGROUND:
Neurofilament light chains (NfL) are cytoskeletal biomarkers of axonal damage, about 40-fold higher in cerebrospinal fluid (CSF) compared to serum, and requiring ultrasensitive techniques to be measured in this latter fluid.OBJECTIVES:
To compare CSF and serum NfL levels in multiple sclerosis (MS) patients using different platforms.METHODS:
60 newly diagnosed relapsing-remitting MS patients (38 females; median age 36.5 years, range 15-60) were enrolled before steroid or disease-modifying treatments. CSF and serum NfL were measured with the commercial Ella™ microfluidic platform (Bio-Techne), the Lumipulse™ Chemiluminescent Enzyme ImmunoAssay (Fujirebio), and the SIMOA™ on the SR-X instrument using NF-light assays (Quanterix).RESULTS:
CSF and serum NfL absolute levels strongly correlated between assays, although being more elevated with Ella™. Passing-Bablok regression showed high agreement in measuring CSF NfL between assays (with greater proportional difference using Ella™), and very high agreement for serum comparing SIMOA™ and Lumipulse™. Similarly, the Bland-Altman comparison evidenced lower biases for Lumipulse™ for both fluids.CONCLUSIONS:
CSF and serum NfL in naïve MS patients are reliably measured with all assays. Although not interchangeable, SIMOA™ and Lumipulse™ showed high agreement for serum and CSF values.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple Recurrente-Remitente
/
Esclerosis Múltiple
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article